Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.56 |
| ▸ | DAO | P14920 | 4/20 | 0.55 |
| ▸ | DDO | Q99489 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8874136 | 0.91 | KDM4E (0.83) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29798542 | 0.86 | KDM4E (0.75) | KDM4EDAODDOMEN1ALDH1A1 | |
| SCHEMBL742657 | 0.86 | KDM4E (0.75) | KDM4EDAODDOMEN1ALDH1A1 | |
| SCHEMBL8873789 | 0.80 | KDM4E (0.67) | KDM4EDAODDOMEN1ALDH1A1 | |
| SCHEMBL38658790 | 0.76 | KDM4E (0.61) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL4030881 | 0.76 | KDM4E (0.61) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL4778716 | 0.74 | DAO (0.68) | KDM4EDAODDOPARP1 | |
| SCHEMBL2151265 | 0.74 | PGR (0.68) | KDM4EDAOALDH1A1LMNAHPGD | |
| SCHEMBL8871521 | 0.74 | DAO (0.62) | KDM4EDAODDOALDH1A1LMNA | |
| SCHEMBL123451 | 0.74 | KDM4E (0.58) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180290985-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| EP-3344250-A2 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | Rexahn Pharmaceuticals, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9969698-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969698-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017040980-A2 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
| EP-0647137-B1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | UNIV CALIFORNIA (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1670774-A1 | QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005033088-A1 | QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-14 | — | — | WO | disclosed |
| US-20050070527-A1 | For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070527-A1 | For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions | HRH4, HRH3, LTB4R | KDM4E 2545/4885GRIN2D 1163/4885GRIN3B 525/4885 |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885GRIN2D 648/4885GRIN3B 1096/4885 |
| US-20180290985-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885GRIN2D 648/4885GRIN3B 1096/4885 |
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885GRIN2D 648/4885GRIN3B 1096/4885 |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885GRIN2D 648/4885GRIN3B 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.